Truist raised the firm’s price target on Tenet Healthcare (THC) to $240 from $225 and keeps a Buy rating on the shares. The firm is updating its model after the company’s Q3 earnings beat and guidance raise, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $235 from $225 at Mizuho
- Tenet Healthcare price target raised to $252 from $230 at RBC Capital
- Tenet Healthcare’s Q3 2025 Earnings Call Highlights Strong Growth
- Tenet Healthcare: Strong Performance and Positive Outlook Drive Buy Rating
- Tenet Healthcare price target raised to $250 from $200 at Raymond James